Gene therapy could be used in two ways in glaucoma: as a drug delivery system, and as a basis for developing new therapies and treatment end points based on the genetic mutations that cause glaucoma.[4] If indeed the TIGR/MYOC gene or separate genes could be shown to be a risk factor for earlier onset or more progressive disease, a patient’s therapeutic end points could be modified based on his or her genetic profile. The gene discussed is MYOC; the disease is glaucoma.